Alpha Teknova (TKNO) Expected to Announce Quarterly Earnings on Thursday

Alpha Teknova (NASDAQ:TKNO) is expected to be issuing its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $9.6190 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 5:30 PM ET.

Alpha Teknova Price Performance

Shares of TKNO opened at $2.06 on Tuesday. The business has a 50-day moving average of $3.28 and a 200-day moving average of $4.30. Alpha Teknova has a 1 year low of $1.91 and a 1 year high of $7.54. The company has a market capitalization of $110.27 million, a price-to-earnings ratio of -5.89 and a beta of 0.41. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.27 and a quick ratio of 4.27.

Institutional Trading of Alpha Teknova

A number of hedge funds have recently bought and sold shares of TKNO. XTX Topco Ltd purchased a new position in Alpha Teknova in the fourth quarter valued at about $77,000. Marshall Wace LLP grew its position in shares of Alpha Teknova by 286.1% in the fourth quarter. Marshall Wace LLP now owns 50,156 shares of the company’s stock valued at $191,000 after purchasing an additional 37,164 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Alpha Teknova during the 4th quarter valued at $239,000. Kestra Private Wealth Services LLC grew its holdings in Alpha Teknova by 80.3% during the 3rd quarter. Kestra Private Wealth Services LLC now owns 79,648 shares of the company’s stock valued at $493,000 after buying an additional 35,469 shares in the last quarter. Finally, PharVision Advisers LLC increased its position in shares of Alpha Teknova by 103.5% during the third quarter. PharVision Advisers LLC now owns 37,645 shares of the company’s stock valued at $233,000 after buying an additional 19,149 shares during the period. 13.81% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alpha Teknova in a research report on Wednesday, January 21st. Zacks Research upgraded shares of Alpha Teknova to a “hold” rating in a report on Wednesday, December 10th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $8.00.

About Alpha Teknova

Alpha Teknova, Inc (NASDAQ: TKNO) is a life science tools and reagents company that develops, manufactures and distributes proprietary products to support research, drug discovery and biomanufacturing. Its offerings target academic institutions, pharmaceutical and biotechnology firms, and diagnostic developers, with a focus on high-purity reagents and optimized workflows designed to accelerate molecular biology and protein science applications.

The company’s portfolio includes molecular biology reagents, cell culture buffers, in vitro translation kits, custom recombinant proteins, high-throughput screening buffers and other specialized formulations.